<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138112</url>
  </required_header>
  <id_info>
    <org_study_id>03-142</org_study_id>
    <nct_id>NCT00138112</nct_id>
  </id_info>
  <brief_title>Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation</brief_title>
  <official_title>Randomized Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Early Viridans Streptococcal Sepsis After Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This is a randomized 2-arm study to compare two different times of giving the drug&#xD;
      vancomycin. Half of the patients will begin vancomycin two days before a bone marrow&#xD;
      transplant. The other half will get it as soon as they have the first fever.&#xD;
&#xD;
      Streptococci are bacteria that live in one's mouth and gut. These bacteria can escape into&#xD;
      the blood when the lining of the mouth and gut weakens from cancer therapy. This can make the&#xD;
      person who is undergoing a bone marrow transplant very sick. All patients who get this&#xD;
      infection are treated with antibiotics. Vancomycin is one drug that is used to treat this&#xD;
      bloodstream infection once it is diagnosed. Studies have shown that giving vancomycin before&#xD;
      a bone marrow transplant seems to prevent this infection. However, giving vancomycin too soon&#xD;
      may increase the chance that the kidneys will be irritated. It may also increase the chance&#xD;
      that other bacteria will become resistant to this drug. We, the investigators at Memorial&#xD;
      Sloan-Kettering Cancer Center, do not know if waiting to start vancomycin until the patient&#xD;
      has a first fever can also prevent this infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is as follows:&#xD;
&#xD;
        -  To compare prophylactic with empirical vancomycin administration for reducing early&#xD;
           viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant&#xD;
           (HSCT) patients.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To examine the safety and tolerability for each vancomycin administration approach.&#xD;
&#xD;
        -  To measure the incidence of vancomycin-resistant enterococcal (VRE) infections for&#xD;
           patients managed with each of the two vancomycin administration approaches.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date>November 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare prophylactic with empirical vancomycin administration for reducing early viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) patients</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability for each vancomycin administration approach</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the incidence of vancomycin-resistant enterococcal (VRE) infections for patients managed with each of the two vancomycin administration approaches</measure>
  </secondary_outcome>
  <enrollment>126</enrollment>
  <condition>Streptococcal Sepsis</condition>
  <condition>Hematologic Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empirical Vancomycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prophylactic Vancomycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients undergoing allogeneic HSCT for hematologic malignancies or other&#xD;
             disorders&#xD;
&#xD;
          -  Conditioning regimen that includes high-dose total body irradiation (TBI) (&gt;1200 cGy)&#xD;
&#xD;
          -  The ability to understand and the willingness to sign the Institutional Review Board&#xD;
             (IRB)-approved Informed Consent, including the Research Authorization component of the&#xD;
             Informed Consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-TBI conditioning regimen&#xD;
&#xD;
          -  Prior history of hypersensitivity to vancomycin (excluding history of &quot;Red Man&#xD;
             Syndrome&quot;)&#xD;
&#xD;
          -  Fever or infection that requires intravenous vancomycin or oral/intravenous linezolid&#xD;
             between day-7 and day-3 before hematopoietic stem cell transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Seo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>September 7, 2006</last_update_submitted>
  <last_update_submitted_qc>September 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2006</last_update_posted>
  <keyword>Streptococcal Sepsis</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Streptococci</keyword>
  <keyword>Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Streptococcal Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

